NanoViricides Inc. (NYSE American: NNVC) Starts Presentation at The LD 500
NanoViricides Inc. (NYSE American: NNVC) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide(R) class of drug candidates is designed to specifically attack enveloped virus particles and dismantle them. The company's lead drug candidate is NV-HHV-101, with its first indication as dermal topical cream for the treatment of shingles rash. The company is in the process of submitting an IND application to the U.S. FDA for this drug candidate. The company cannot project an exact date for filing an IND because of its dependence on a number of external collaborators and…







